Dynavax Technologies Corporation
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

Abstract:

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.